Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 20, Issue 3, 2011, Pages 218-233

  Pringsheim, Tamara ^a   Panagiotopoulos, Constadina ^a   Davidson, Jana ^a   Ho, Josephine ^a  

^a CAMESA guideline group ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CONSENSUS; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GLUCOSE METABOLISM; GYNECOMASTIA; HEALTH CARE QUALITY; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPEROSMOLAR COMA; LABORATORY TEST; MENSTRUATION DISORDER; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; OROFACIAL DYSKINESIA; PANCREATITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; PSYCHOMOTOR DISORDER; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREMOR; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 80051608049     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Group, R. D. B. S. (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. The American Journal of Psychiatry, 159(8), 1337-1346.
2. American Diabetes Association, A. P. A. (2004). Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, 27(2), 596-601.
3. Anderson, G., Scahill, L., McCracken, J., McDougle, C., Aman, M., Tierney, E., Vitiello, B. (2007). Effects of Short-and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism. Biological Psychiatry, 61(4), 545-550.
4. Arango, C., Robles, O., Parellada, M., Fraguas, D., Ruiz-Sancho, A., Medina, O., Moreno, D. (2009). Olanzapine compared to quetiapine in adolescents with a first psychotic episode. European Child & Adolescent Psychiatry, 18(7), 418-428.
5. Armenteros, J. L., Lewis, J. E., & Davalos, M. (2007). Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. Journal of the American Academy of Child & Adolescent Psychiatry, 46(5), 558-565.
6. AstraZeneca. (2008). Seroquel. In A. Z. C. Inc (Ed.) (pp. 1-50). Mississauga: Astra Zeneca Canada Inc.
7. Baker, J., Olesen, L., & Sorensen, T. (2007). Childhood body mass index and the risk of coronary heart disease in adulthood. New England Journal of Medicine, 357(23), 2329-2337.
8. Biederman, J., Mick, E., Spencer, T., Dougherty, M., Aleardi, M., & Wozniak, J. (2007). A prospective open label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disorders, 9, 888-894.
9. Blair, J., & Taggart, B. (2004). Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. Journal of Neural Transmission, 111 (7), 791-815.
10. Buitelaar, J., van der Gaag, R., Cohen-Kettenis, P., & Melman, C. (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. The Journal of Clinical Psychiatry, 62(4), 239-248.
11. Calarge, C., Acion, L., Kuperman, S., Tansey, M., & Schlechte, J. (2009). Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 19(2), 101-109.
12. Castro-Fornieles, J., Parellada, M., Soutullo, C. A., Baeza, I., Gonzalez-Pinto, A., Graell, M., Arango, C. (2008). Antipsychotic treatment in child and adolescent first-episode psychosis: A longitudinal naturalistic approach. Journal of Child and Adolescent Psychopharmacology, 18(4), 327-336.
13. Connor, D. F., McLaughlin, T. J., & Jeffers-Terry, M. (2008). Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. Journal of Child and Adolescent Psychopharmacology, 18(2), 140-156.
14. Correll, C. (2008). Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. International Review of Psychiatry, 20(2), 195-201.
15. Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. The Journal of the American Medical Association, 302(16), 1765-1773.
16. Croonenberghs, J., Fegert, J. M., Findling, R. L., De Smedt, G., Van Dongen, S., & Group, R. D. B. S. (2005). Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. Journal of the American Academy of Child and Adolescent Psychiatry, 41(1), 64-72.
17. DelBello, M., Adler, C., Whitsel, R., Stanford, K., & Strakowski, S. (2007). A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. Journal of Clinical Psychiatry, 68(5), 789-795.
18. DelBello, M., Chang, K., Welge, J., Adler, C., Rana, M., Howe, M., Strakowski, S. (2009). A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disorders, 11(5), 483-493.
19. DelBello, M. P., Schwiers, M. L., Rosenberg, H. L., & Strakowski, S. M. (2002). A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry, 41(10), 1216-1223.
20. DelBello, M. P., Versavel, M., Ice, K., Keller, D., & Miceli, J. (2008). Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. Journal of Child and Adolescent Psychopharmacology, 18(5), 491-499.
21. Dittmann, R. W., Meyer, E., Freisleder, F. J., Remschmidt, H., Mehler-Wex, C., Junghanss, J., Wehmeier, P. (2008). Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: Results from a large, prospective, open-label study. Journal of Child and Adolescent Psychopharmacology, 18(1), 54-69.
22. Findling, R., Marcus, R., Kamen, L., Manos, G., McQuade, R., Carson, W., Owen, R. (2009). 52 week open label study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of irritability in children and adolescents with autistic disorder. Poster presentation. 48th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood Florida, December 6-10, 2009.
23. Findling, R., Nyilas, M., Forbes, R., McQuade, R., Jin, N., Iwamoto, T., Chang, K. (2009). Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 70(10), 1441-1451.
24. Findling, R. L., McNamara, N. K., Branicky, L. A., Schluchter, M. D., Lemon, E., & Blumer, J. L. (2000). A double-blind pilot study of risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39(4), 509-516.
25. Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S., Carson, W. (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American Journal of Psychiatry, 165(11), 1432-1441.
26. Fleischhaker, C., Heiser, P., Hennighausen, K., Herpertz-Dahlmann, B., Holtkamp, K., Mehler-Wex, C., Warnke, A. (2008). Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. Journal of Neural Transmission, 115(11), 1599-1608.
27. Fraguas, D., Merchan-Naranjo, J., Laita, P., Parellada, M., Moreno, D., Ruiz-Sancho, A., Arango, C. (2008). Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Journal of Clinical Psychiatry, 69(7), 1166-1175.
28. Gogtay, N., Sporn, A., Alfaro, C., Mulqueen, A., & Rapoport, J. (2002). Clozapine induced akathisia in children with schizophrenia. Journal of Child and Adolescent Psychopharmacology, 12(4), 347-349.
29. Guyatt, G., Oxman, A., Vist, G., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., GRADE Working Group. (2008). GRADE: An emerging consensus on rating quality of evidence and strength or recommendations. BMJ, 336, 924-926.
30. Haas, M., DelBello, N., Pandina, G., Kushner, S., Van Hove, I., Augustyns, I., Kusumakar, V. (2009). Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disorders, 11(7), 687-700.
31. Haas, M., Unis, A., Armenteros, J., Copenhaver, M., Quiroz, J., & Kushner, S. (2009). A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. Journal of Child and Adolescent Psychopharmacology, 19(6), 611-621.
32. Harris, R., Helfand, M., Woolf, S., Lohr, K., Mulrow, C., Teutsch, S., Atkins, D. (2001). Current methods of the U.S. Preventive Services Task Force. A review of the process. American Journal of Preventive Medicine, 20(3S), 21-35.
33. Hollander, E., Wasserman, S., Swanson, E., Chaplin, W., Schapiro, M., Zagursky, K., & Novotny, S. (2006). A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive development disorder. Journal of Child and Adolescent Psychopharmacology, 16(5), 541-548.
34. Juonala, M., Jarvisalo, M., &N., M.-T. (2005). Risk factors identified in childhood and decreased carotid artery elasticity in adulthood. Circulation, 112, 1486-1493.
35. Koller, E., Cross, J., Doraiswamy, P., & Schneider, B. (2003). Risperidone induced diabetes mellitus: A pharmacovigilance study. Pharmacotherapy, 23(6), 735-744.
36. Koller, E., Weber, J., Doraiswamy, P., & Schneider, B. (2004). A survey of reports of quetiapine associated hyperglycemia and diabetes mellitus. Journal of Clinical Psychiatry, 65, 857-863.
37. Koller, E. A., Cross, J. T., Doraiswamy, P. M., & Malozowski, S. N. (2003). Pancreatitis associated with atypical antipsychotics: From the food and drug administration's medwatch surveillance system and published reports. Pharmacotherapy, 23(9), 1123-1130.
38. Kryzhanovskaya, L., Schulz, S. C., McDougle, C., Frazier, J., Dittmann, R., Robertson-Plouch, C., Tohen, M. (2009). Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry, 48(1), 60-70.
39. Kumra, S., Frazier, J., Jacobsen, L., McKenna, K., Gordon, C., Lenane, M., Rapoport, J. (1996). Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Archives of General Psychiatry, 53(12), 1090-1097.
40. Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Cullen, K., Kane, J. (2008). Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: An open-label extension study. Journal of Child and Adolescent Psychopharmacology, 18(4), 307-316.
41. Kumra, S., Kranzler, H., Gerbinorosen, G., Kester, H., Dethomas, C., Kafantaris, V., Kane, J. (2008). Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biological Psychiatry, 63(5), 524-529.
42. Malone, R., Delaney, A., Hyman, S., & Cater, J. (2007). Ziprasidone in adolescents with autism: An open label pilot study. Journal of Child and Adolescent Psychopharmacology, 17(6), 779-790.
43. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 48(11), 1110-1119.
44. Mattson, N., Ronnemaa, T., & Juonala, M. (2008). Childhood predictors of the metabolic syndrome in adulthood. The cardiovascular risk in young finns study. Annals of Medicine, 40, 542-552
45. McDougle, C., Kem, D., & Posey, D. (2002). Case series: Use of ziprasidone for maladaptive symptoms in youth with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41(8), 921-927.
46. Milin, R., Simeon, J., Batth, S., Thatte, S., Dare, G., & Walker, S. (2006). An open trial of olanzapine in children and adolescents with asperger disorder. Journal of Clinical Psychopharmacology, 26(1), 90-92.
47. Morato, E., Druss, B., & Harung, D. (2010). Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second generation antipsychotic drugs. Archives of General Psychiatry, 67(1), 17-24.
48. Mozes, T., Ebert, T., Michal, S., Spivak, B., & Weizman, A. (2006). An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. Journal of Child and Adolescent Psychopharmacology, 16(4), 393-403.
49. Mozes, T., Greenberg, Y., Spivak, B., Tyano, S., Weizman, A., & Mester, R. (2003). Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: An open-label study. Journal of Child and Adolescent Psychopharmacology, 13(3), 311-317.
50. Novartis (2010). Clozaril. In Novartis (Ed.) (pp. 1-32). East Hanover: Novartis Pharmaceutical Corporation.
51. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Findling, R. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533-1540.
52. Panagiotopoulos, C., Ronsley, R., Elbe, D., Davidson, J., & Smith, D. (2010). First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 19(2), 124-137.
53. Pringsheim, T., Lam, D., Ching, K., & Patten, S. (2011). Metabolic and neurological complications of second generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Safety, In press.
54. Pringsheim, T., Lam, D., & Patten, S. (2010). Pharmacoepidemiology of Second Generation Antipsychotics in Canadian Children: 2005 to 2009. Paper presented at the American Academy of Child and Adolescent Psychiatry.
55. Pulkki-Raback, L., Elovainio, M., & M., K. (2009). Depressive symptoms and the metabolic syndrome in childhood and adulthood: A prospective cohort study. Health Psychology, 28(1), 108-116.
56. Ratzoni, G., Gothelf, D., Brand-Gothelf, A., Reidman, J., Kikinzon, L., Gal, G., Weizman, R. (2002). Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry, 41(3), 337-343.
57. Research Units on Pediatric Psychopharmacology Autism Network (2002). Risperidone in children with autism and serious behavioural problems. The New England Journal of Medicine, 347(5), 314-321.
58. Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behaviour disorders. The American Journal of Psychiatry, 163(3), 402-410.
59. Reyes, M., Croonenberghs, J., Augustyns, I., & Eerdekens, M. (2006). Long-term use of risperidone in children with disruptive behaviour disorders and subaverage intelligence: Efficacy, safety, and tolerability. Journal of Child and Adolescent Psychopharmacology, 16(3), 260-272.
60. Ross, R., Novins, D., Farley, G., & Adler, L. (2003). A 1-year open-label trial of olanzapine in school-age children with schizophrenia. Journal of Child and Adolescent Psychopharmacology, 13(3), 301-309.
61. Sallee, F., Kurlan, R., Goetz, C., Signer, H., Scahill, L., Law, G., Chappell, P. (2000). Ziprasidone treatment of children and adolescents with tourette's syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 39(3), 292-299.
62. Schimmelmann, B. G., Mehler-Wex, C., Lambert, M., Schulze-zur-Wiesch, C., Koch, E., Flechtner, H. H., Schulte-Markwort, M. (2007). A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 17(6), 768-778.
63. Seo, W. S., Sung, H.-M., Sea, H. S., & Bai, D. S. (2008). Aripiprazole treatment of children and adolescents with tourette disorder or chronic tic disorder. Journal of Child and Adolescent Psychopharmacology, 18(2), 197-205.
64. Shaw, P., Sporn, A., Gogtay, N., Overman, G., Greenstein, D., Gochman, P., Rapoport, J. (2006). Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Archives of General Psychiatry, 63(7), 721-730.
65. Shea, S. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634-e641.
66. Sikich, L., Frazier, J., McClellan, J., Findling, R., Vitiello, B., Ritz, L., Lieberman, J. (2008). Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the Treatment of Early-onset Schizophrenia Spectrum Disorders (TEOSS) Study. American Journal of Psychiatry, 165(11), 1420-1431.
67. Sikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., & Lieberman, J. A. (2004). A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29(1), 133-145.
68. Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., Carroll, A, & Risperidone Conduct Study Group. (2002). Effects of risperidone on conduct and disruptive behaviour disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry, 41(9), 1026-1036.
69. Stigler, K., Diener, J., Kohn, A., Li, L., Erickson, C., Posey, D.,& McDougle, C. (2009). Aripiprazole in pervasive developmental disorder not otherwise specified and asperger's disorder: A 14-week, prospective, open-label study. Journal of Child and Adolescent Psychopharmacology, 19(3), 265-274.
70. Tohen, M., Kryzhanovskaya, L., Carlson, G., DelBello, M., Wozniak, J., Kowatch, R., Biederman, J. (2007). Olanzapine versus placebo in the treatment of adolescents with bipolar mania. American Journal of Psychiatry, 164(10), 1547-1556.
71. Tramontina, S., Zeni, C., Ketzer, C., Pheula, G., Narvaez, J., & Rohde, L. (2009). Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: A pilot randomized clinical trial. Journal of Clinical Psychiatry, 70(5), 756-764.
72. Turrone, P., Kapur, S., Seeman, M., & Flint, A. (2002). Elevation in prolactin levels by atypical antipsychotics. American Journal of Psychiatry, 159(1), 133-135.
73. Van Bellinghen, M., & De Troch, C. (2001). Risperidone in the treatment of behavioural disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11(1), 5-13.